>>what do you make of last two days...volume and price?>>
Maybe, it has something to do with the following publication.
'Hedgehog' Pathway Key to Colon Cancer Therapy
(Ivanhoe Newswire) -- Scientists in Switzerland have discovered a way to block the growth of human colon cancer cells, preventing the disease from reaching advanced stages and developing liver metastases. The research shows that blocking the so-called Hedgehog-GLI pathway can prevent the growth of tumors, metastatic lesions and cancer stem cells, the cells thought to lie at the root of cancer growth.
Colon cancer often begins in a treatable form when it is confined to the bowel wall, but later it can develop to an incurable metastatic stage. A Geneva-based research team has discovered the essential role played by HH-GLI in the progression of colon cancer to these late and incurable stages. HH-GLI is a signaling pathway used by cells to communicate with each other to determine position, growth and survival.
"Previous works hinted at the possible role of HH-GLI in colon cancer, but this was denied by other studies, so its involvement was never entirely clear," lead researcher Professor Ariel Ruiz i Altaba of Geneva University is quoted as saying. "In this study we have proven that HH-GLI is essential for the development and growth of colon cancers. The research demonstrates the active presence of HH-GLI signaling in epithelial cells of colon cancers. Moreover, we find that metastatic tumors rely on this pathway for sustained growth. This identifies HH-GLI as a target for novel anti-cancer therapies against so-far incurable forms of colon cancer in distant organs, such as the liver."
This research opens the possibility of new anti-cancer therapies, specifically the use of RNA interference and of Cyclopamine, a plant product known to block Hedgehog pathway activity. This and other similar molecules can now be considered for future research as a treatment for terminal patients with metastatic disease and to fight resurgent forms of the disease.
"Recurrence is a major problem in cancer treatment. Even after a patient has displayed an apparent complete recovery from a primary tumor, recurrence at nearby or distal locations has a poor prognosis," said Ruiz i Altaba. "While monitoring recovering mice we noted that tumors began to recur in all cases except for those treated with Cyclopamine for a short period of time after tumor disappearance. The treated mice were kept for up to one year after the treatment and remained healthy and tumor free."
Using these genetic or pharmacologic methods to block HH-GLI activity also prevents cancer stem cell self-renewal. Using a new in vivo assay to test the participation of cancer stem cells in a growing tumor, the research team demonstrated the essential role of this pathway for the maintenance and survival of cancer stem cells.
"This work firmly establishes the critical action of HH-GLI in human colon cancer cells, providing the platform for preclinical and future clinical work." concluded Ruiz i Altaba. "The finding that a blockade of HH-GLI for a relatively short period was sufficient to eliminate the tumor and prevent recurrence, without negatively affecting the health of the mice opens the possibility for the use of a therapeutic window to eradicate the tumor without major side effects."
SOURCE: EMBO Molecular Medicine, August, 2009
GDC-0449 is in a midstage trial for this indication. Fror Curis' website:
GDC-0449 (Hedgehog Pathway Inhibitor) (Colorectal)
Under Collaboration with Genentech
About the GDC-0449 Colorectal Cancer Phase II Clinical Trial
In May 2008, Genentech initiated a Phase II clinical trial of GDC-0449 in metastatic colorectal cancer. GDC-0449 is being evaluated in approximately 190 patients with metastatic colorectal cancer in combination with the current standard of care in a randomized, placebo-controlled, double-blind Phase II trial. Patients receive either FOLFOX or FOLFIRI chemotherapy in combination with Avastin and are randomized to receive GDC-0449 or placebo. The primary objective of the trial is progression-free survival from randomization to disease progression or death. Secondary outcome measures include the measurement of Hedgehog protein expression in archival tissue and tracking of adverse events. Genentech has stated that it expects data from this trial in the 2nd half of 2010. |
